Status:
COMPLETED
Everolimus Stent in Patients With Coronary Artery Disease (CAD)
Lead Sponsor:
San Giuseppe Moscati Hospital
Conditions:
Coronary Artery Disease
Coronary Atherosclerosis
Eligibility:
All Genders
18-85 years
Phase:
PHASE3
Brief Summary
Aim of the study is to compare the everolimus eluting stent and sirolimus eluting stent in all comers PCI eligible patients
Detailed Description
Compared with the currently available first-generation drug-eluting stents (DES), second-generation DES have been designed with the goal of improving safety and efficacy. Everolimus, a sirolimus analo...
Eligibility Criteria
Inclusion
- All patients with coronary artery disease eligible for percutaneous coronary intervention (PCI)
Exclusion
- Contraindication to dual antiplatelet therapy for 12 months
- Known allergy to sirolimus or everolimus
- Major surgical procedure planned within 1 month
- History, symptoms, or findings suggestive of aortic dissection.
- Participation in other trials
- Pregnancy
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT01182649
Start Date
March 1 2007
End Date
June 1 2010
Last Update
August 17 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Cardiology Aorn Moscati
Avellino, Italy, 83100